Entries by Thomas Gabrielczyk

Lead optimisation – the sequence is the key

The efficacy of therapeutic antibodies is defined by their primary amino acid sequence. ­After discovery, antibody candidates often profit from protein engineering and sequence optimisation. ­Different technologies can improve the functional properties of antibodies as well as their biochemical and biophysical characteristics influencing manufacturing, process development, formulation, and other parameters of the final drug target product profile.

A new purification workflow

Biologicals have shown significant success for more complex diseases, whereas small molecule drugs have not been that effective. New biologicals are mostly highly purified proteins or antibodies, which require the development of technologies for the preparation of a large number of drug candidates with high purity and speed. A high throughput magnetic beads-based ­system is a game-changer for biologics discovery.

Creating a safe ultra-low cold storage environment

In recent years, several beneficial cell samples and microbial strains have been discovered, engineered, and studied, resulting in scientific discoveries and other technological breakthroughs such as vaccines and medicines benefitting communities all around the world. However, several medical products tend to require very low temperatures for storage, making Ultra-Low Freezers increasingly important to maintain their viability.